India-based Cipla has been expanding its manufacturing footprint outside of its base in India and has now made the jump across the Arabian Sea to Yemen.
Novotech, which bills itself as Australia's largest CRO, has signed a deal with a South Korean outfit to help bolster the country's status among global drug development locales.
A team from the Massachusetts Institute of Technology is a finalist for the 2014 Hult Prize after developing a simple wound-therapy device to improve the lives of those lacking access to adequate medical care.
Roche and Cipla are writing a new chapter in the bitter battles that have been fought by Western drugmakers over their patents in India. They are in mediation over the patent for Roche's blockbuster cancer fighter Tarceva, in what may be the first case to take this route.
Big Pharma's reputation in China has taken a bruising in the last year after an investigation into GlaxoSmithKline's use of bribery to power sales there spilled over to questions into Roche, Novo Nordisk and others. So what's the industry to do to burnish its image and smooth over the situation with authorities? Hire Chinese nationals who can figure out the puzzle box that is Chinese healthcare.
To avoid the fate of some of its competitors that have run afoul of the FDA over loose manufacturing standards, Dr. Reddy's and some other Indian drugmakers have decided it is worth investing hundreds of millions of dollars for new plants and equipment in a country that has traditionally relied on cheap human labor.
Lincoln, NE, CRO Celerion has opened up shop in Singapore, following through on its efforts to tap the fast-growing Asian market for clinical research.
Turkey is a fast-growing market expected to be worth about $22.8 billion by the end of 2015. Domestic drugmakers, along with Big Pharma, are expanding manufacturing there to keep up with demand.
Back in 2012, the GAVI Alliance announced plans to help immunize 30 million girls in 40 countries with HPV vaccines by 2020. Wednesday, the Children's Investment Fund Foundation chipped in toward that goal with a $25 million investment that will be matched through the U.K.'s Department of International Development.
Multinationals may lose some of their access to Russia's vaccines market thanks to pressure from state corporation Rosteh, with 11 billion rubles ($300 million) in state contracts at stake.